Photo taken from Talha Badar/X
Apr 1, 2024, 23:39
Talha Badar: A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
Talha Badar, Hematologist/Oncologist at Mayo Clinic, shared a post on X/Twitter:
“A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
3+3 model with 4 INO dose levels: 0.3 mg/m2, 0.4 mg/m2, 0.5 mg/m2, and 0.6 mg/m2.
19 patients treated, dose-limiting toxicity (DLT) was thrombocytopenia.”
View the article attached to the post.
Source: Talha Badar/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 16:13
Nov 14, 2024, 16:03
Nov 14, 2024, 15:58
Nov 14, 2024, 15:54
Nov 14, 2024, 15:53
Nov 14, 2024, 15:50
Nov 14, 2024, 15:49
Nov 14, 2024, 15:40
Nov 14, 2024, 15:37
Nov 14, 2024, 15:25